There was enough evidence to show that both statins and ω−3 fatty acids, reduce triglyceride levels in type 2 diabetes patients. However, when it comes to the reduction of cardiovascular outcomes, the pooled relative risk from statins showed no significant reduction in cardiovascular outcomes from the baseline as opposed to ω−3 fatty acids, which indicated a significant decrease. The benefits of using statins in T2DM patients were outweighed by the side impacts as opposed to the usage of n-3. : Concerning type 2 diabetes patients, we found that ω−3 fatty acids were the best choice of medication in reducing triglyceride levels and cardiovascular outcomes.